ArticleAmerican journal of cancer research2022
Prrx1 promotes resistance to temozolomide by upregulating ABCC1 and inducing vasculogenic mimicry in glioma.
Article in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 9 citations in OpenAlex.
- Molecular and clinical stratification of astroblastomas: Three distinct fusion-defined groups informing risk-adapted treatment strategies.Neuro-oncology · 2026Article
- Targeting ABC transporters in glioma: farnesiferols as potent agents against chemotherapy resistance.Neurogenetics · 2026Article
- Dissecting the aberrant vasculature of glioblastoma: mechanisms and therapeutic targets.Cancer metastasis reviews · 2026Review
- Current evidence and challenges of multitarget anti-angiogenic agents for glioblastoma: Results from clinical trials.iScience · 2025Review
- The Roles of RNA-Binding Proteins in Vasculogenic Mimicry Regulation in Glioblastoma.International journal of molecular sciences · 2025Review
- Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.Acta neuropathologica communications · 2025Review
- Revisiting ABC Transporters and Their Clinical Significance in Glioblastoma.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2023Review
- MOGS promotes stemness acquisition and invasion via enhancing NOTCH1-glycosylation dependent NOTCH pathway in colorectal cancer.American journal of cancer research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are the most common primary brain tumors with dismal prognoses. Temozolomide (TMZ), the frontline therapeutic agent for gliomas, has shown limited clinical benefit primarily due to the acquired chemoresistance. Although growing evidence has suggested that the multi-drug resistance phenotype and abnormal vascular microenvironment are responsible for the intrinsic and extrinsic TMZ resistance, the molecular mechanism of TMZ resistance remains to be elucidated. In this study, we found Paired-related homeobox 1 (Prrx1) was an independent prognostic factor for the efficacy of chemotherapy-based postoperative treatment. Silencing Prrx1 markedly enhanced the TMZ-induced cytotoxicity both in vitro and in vivo. We also demonstrated that Prrx1 increased the expression of ABCC1, a member of ATP-Binding Cassette (ABC) transporter protein family, through binding to the promoter region of ABCC1 gene and initiating its transcription. Silencing ABCC1 mitigated the TMZ resistance induced by Prrx1. Furthermore, Prrx1 facilitates the formation of vasculogenic mimicry (VM), a critical extrinsic mechanism for glioma TMZ resistance. Collectively, our findings supported the critical role of Prrx1 in TMZ resistance via intrinsic and extrinsic mechanism. Targeting Prrx1 might represent a feasible strategy to overcome therapeutic resistance in glioma.
Indexed as
Identifiers
36119823PMC9441999W4296328011What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.